Nicholas Kalayeh, MD
Interventional Cardiology · Henderson, NVNPI 1134335607
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,503 of the $10,731 with a category attached, or 88.6%. 37 manufacturers reported payments, led by Abbott at 28.6% of the total. Reporting peaked in 2022 at $3,241 and has fallen 76.2% since, to $773 in 2025.
Across 255 payments — averaging $42.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$2K
- Bard Peripheral Vascular, Inc.$870
- Abiomed$774
- Cvrx, Inc.$518
- Novartis$487
- plus $3K from 31 others
Across 8 payments — averaging $808.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$6K
What the payments were for
- Travel & lodging$1,21211%
- Food & beverage$9,50389%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 49 | $3,072 |
| Medtronic(2 entities) | 27 | $1,568 |
| Bard Peripheral Vascular, Inc. | 10 | $870 |
| Abiomed | 10 | $774 |
| Cvrx, Inc. | 6 | $518 |
| Novartis | 26 | $487 |
| Boston Scientific | 5 | $395 |
| Penumbra, Inc. | 2 | $322 |
| E.r. Squibb & Sons, L.L.C. | 14 | $320 |
| Novo Nordisk | 11 | $297 |
| Inari Medical, Inc. | 2 | $232 |
| Philips North America LLC | 8 | $199 |
| Johnson & Johnson | 13 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $152 |
| Sanofi-aventis U.S. LLC | 7 | $145 |
| Amgen | 8 | $138 |
| Pfizer | 6 | $118 |
| Boehringer Ingelheim | 5 | $115 |
| Acist Medical Systems, Inc. | 1 | $111 |
| Lexicon Pharmaceuticals, Inc. | 5 | $93 |
| AstraZeneca | 4 | $72 |
| Bayer | 4 | $64 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| Cardiovascular Systems Inc. | 4 | $53 |
| Irhythm Technologies, Inc. | 2 | $47 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Merck | 2 | $37 |
| Impulse Dynamics (USA) Inc. | 1 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Lantheus Medical Imaging, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Teleflex LLC | 1 | $17 |
| Shockwave Medical, Inc | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,181
- Barostim Neo System$422
- Impella$406
- LINQ II$288
- Indigo System$200
- FLOWTRIEVER CATHETER, S$197
- CT THROMBECTOMY SYSTEM KIT$197
- GENERAL ATHERECTOMY$170
- CoreValve Evolut$159
- Cobalt$158
- Confirm Rx$144
- COROFLOW$141
- GENERAL - THERAPIES$139
- Micra$138
- 3F$137
- MERLIN@HOME$136
- AZURE XT DR MRI SURESCAN$131
- MitraClip$125
- Ruby$122
- CAMZYOS$118
How this compares
$10,731 in reported general payments places this provider in the 55th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArcalystRilonacept | 12 | $276,659 |
| EliquisApixaban | 153 | $201,326 |
| EntrestoSacubitril/Valsartan | 49 | $61,830 |
| XareltoRivaroxaban | 38 | $55,061 |
| FarxigaDapagliflozin Propanediol | 13 | $18,772 |
| Repatha SureclickEvolocumab | 26 | $18,711 |
| BrilintaTicagrelor | 20 | $18,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $11,285 |
| Midodrine Hcl | 30 | $5,253 |
| Metoprolol Succinate | 218 | $3,437 |
| Ranolazine ErRanolazine | 21 | $3,086 |
| Amiodarone Hcl | 78 | $2,524 |
| Rosuvastatin Calcium | 55 | $2,364 |
| Atorvastatin Calcium | 252 | $1,998 |
| Doxazosin Mesylate | 63 | $1,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kiniksa Pharmaceuticals International, PLCArcalyst | $26 | $276,65912 claims |
| PfizerEliquis | $118 | $201,326153 claims |
| NovartisEntresto | $487 | $61,83049 claims |
| Johnson & JohnsonXarelto | $198 | $55,06138 claims |
| AstraZenecaFarxiga, Brilinta | $72 | $36,98533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Henderson
- Jeffrey LevismanHenderson$226K
- Howard BroderHenderson$168K
- Karthiek NaralaHenderson$44K
- Dane JeficHenderson$17K
- Cam ChojiHenderson$8K
- Cres MirandaLas Vegas$660K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Neville MistryLas Vegas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.